We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+37.43%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$239M
Cap. Flow
+$108M
Cap. Flow %
8.34%
Top 10 Hldgs %
67.1%
Holding
47
New
6
Increased
10
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$35.2M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$24.6M
3
ALLK
Allakos
ALLK
+$20.1M
4
VRNA
Verona Pharma
VRNA
+$17.7M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.9M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$47.9M
2
VRDN icon
Viridian Therapeutics
VRDN
+$11.3M
3
PCVX icon
Vaxcyte
PCVX
+$6.08M
4
KRYS icon
Krystal Biotech
KRYS
+$5.56M
5
PASG icon
Passage Bio
PASG
+$2.47M

Sector Composition

Rank Sector Weight
1 Healthcare 98.83%
2 Miscellaneous 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
1
DELISTED
HilleVax
HLVX
$167M 12.84%
9,758,359
+472,677
+5% +$6.87M
ARQT icon
2
Arcutis Biotherapeutics
ARQT
$2.99B
$166M 12.78%
8,684,232
+250,000
+3% +$5.66M
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$743M
$93.2M 7.17%
8,407,152
+2,579,737
+44% +$24.6M
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$83.9M 6.46%
4,265,559
+670,533
+19% +$13.4M
SNDX icon
5
Syndax Pharmaceuticals
SNDX
$1.74B
$82M 6.31%
3,412,838
+217,435
+7% +$4.88M
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$5.94B
$80.4M 6.19%
3,827,781
+260,869
+7% +$6.28M
KRYS icon
7
Krystal Biotech
KRYS
$10.4B
$71M 5.47%
1,018,388
-77,019
-7% -$5.56M
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.38B
$46.4M 3.57%
+1,894,000
New +$35.2M
IMGO
9
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$44.7M 3.44%
2,971,274
– –
PCVX icon
10
Vaxcyte
PCVX
$8.9B
$37.1M 2.86%
1,547,405
-240,000
-13% -$6.08M
COGT icon
11
Cogent Biosciences
COGT
$6.02B
$30.9M 2.38%
2,074,154
-20,000
-1% -$274K
TARS icon
12
Tarsus Pharmaceuticals
TARS
$3.15B
$30.6M 2.36%
1,787,527
– –
ALLK
13
DELISTED
Allakos
ALLK
$29.3M 2.26%
+4,792,000
New +$20.1M
CRNX icon
14
Crinetics Pharmaceuticals
CRNX
$9B
$27.8M 2.14%
1,414,823
– –
TCDA
15
DELISTED
Tricida, Inc. Common Stock
TCDA
$26.7M 2.06%
2,549,671
+467,578
+22% +$5.11M
ANAB icon
16
AnaptysBio
ANAB
$1.67B
$23M 1.77%
899,700
– –
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$22.8M 1.76%
1,572,192
– –
ALPN
18
DELISTED
Alpine Immune Sciences Inc
ALPN
$21.5M 1.66%
2,985,757
– –
VRNA
19
DELISTED
Verona Pharma
VRNA
$21.5M 1.65%
+2,099,541
New +$17.7M
FLACU
20
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$15.2M 1.17%
1,501,000
– –
MRUS
21
DELISTED
Merus
MRUS
$15M 1.15%
746,479
+72,500
+11% +$1.73M
ACAD icon
22
Acadia Pharmaceuticals
ACAD
$5.02B
$14M 1.08%
+857,338
New +$13.9M
REPL icon
23
Replimune Group
REPL
$1.46B
$13.9M 1.07%
806,267
– –
GRTS
24
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$13.5M 1.04%
5,237,348
– –
ARVN icon
25
Arvinas
ARVN
$600M
$12.7M 0.98%
285,331
– –
1
2

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q3 2022 Portfolio in Review

As of Q3 2022, Frazier Life Sciences Management held 47 positions worth $1.3B, up 23% from $1.06B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Frazier Life Sciences Management deployed $108M of net new capital in Q3 2022, opening 6 new positions and adding to 10 existing holdings. Its largest new stake was Rhythm Pharmaceuticals: 1,894,000 shares worth $46.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Vaxcyte, an estimated $6.08M trimmed.

  • Frazier Life Sciences Management's largest Q3 2022 buy was Rhythm Pharmaceuticals: 1,894,000 shares worth $46.4M.
  • Frazier Life Sciences Management added most to Phathom Pharmaceuticals in Q3 2022, an estimated $24.6M increase.
  • Frazier Life Sciences Management's biggest Q3 2022 reduction was Vaxcyte, cutting an estimated $6.08M.
  • Frazier Life Sciences Management fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $47.9M.
  • Frazier Life Sciences Management's ten largest holdings make up 67% of its $1.3B portfolio in Q3 2022.
  • Frazier Life Sciences Management opened 6 new positions and closed 4 in Q3 2022.
  • Frazier Life Sciences Management's portfolio value rose 23% quarter-over-quarter to $1.3B.

Based on Frazier Life Sciences Management's 13F filing for Q3 2022, filed 14 Nov 2022.